Like_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":806038929,"tweetId":"806038929","gmtCreate":1627615501861,"gmtModify":1631883857792,"author":{"id":3573174299397007,"idStr":"3573174299397007","authorId":3573174299397007,"authorIdStr":"3573174299397007","name":"Khairul0802","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/806038929","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"tweetType":1,"viewCount":2027,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/806038929"}